Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

UNC professor, Nobel laureate Aziz Sancar inspires the next generation
A decade after earning the Nobel Prize in chemistry, UNC School of Medicine professor Dr. Aziz Sancar shows no signs of hanging up his lab...
Sun May 3, 2026

Meet the Carolina Class of 2026
More than 7,100 Tar Heels, including undergraduate, graduate and professional students, will have their Carolina degrees conferred at Spring Commencement on May 9. More than...
Sat May 2, 2026

When a Cold War trip to the USSR turned into a bizarre basketball game for UNC faculty and students
50 yrs ago, one of the most bizarre & hilariously mismatched basketball games in UNC history took place – and almost no one knows about...
Wed Apr 29, 2026

‘A space to breathe:’ The Coker Arboretum’s enduring legacy
There once was just one tree in the space that is now the Coker Arboretum. More than 120 years later, that overcup oak still stands...
Mon Apr 27, 2026